[go: up one dir, main page]

PE20070647A1 - 3-ALKYLAZETHYL DINE DERIVATIVES SUBSTITUTED WITH HETEROCICLES AS ANTAGONISTS OF CANABINOID RECEPTOR 1 (CB1) - Google Patents

3-ALKYLAZETHYL DINE DERIVATIVES SUBSTITUTED WITH HETEROCICLES AS ANTAGONISTS OF CANABINOID RECEPTOR 1 (CB1)

Info

Publication number
PE20070647A1
PE20070647A1 PE2006001495A PE2006001495A PE20070647A1 PE 20070647 A1 PE20070647 A1 PE 20070647A1 PE 2006001495 A PE2006001495 A PE 2006001495A PE 2006001495 A PE2006001495 A PE 2006001495A PE 20070647 A1 PE20070647 A1 PE 20070647A1
Authority
PE
Peru
Prior art keywords
methyl
alkylazethyl
antagonists
fluoro
heterocicles
Prior art date
Application number
PE2006001495A
Other languages
Spanish (es)
Inventor
Robert K Baker
Jeffrey J Hale
Kathleen M Rupprecht
Shouwu Miao
Original Assignee
Merck & Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck & Co Inc filed Critical Merck & Co Inc
Publication of PE20070647A1 publication Critical patent/PE20070647A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Diabetes (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Addiction (AREA)
  • Psychiatry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Child & Adolescent Psychology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

SE REFIERE A COMPUESTOS DERIVADOS DE 3-ALQUILAZETIDINA DE FORMULA (I) DONDE X ES HIDROXI, NH2, METILO O METOXI; R2 Y R3 SON CADA UNO H, METILO, TRIFLUOROMETILO, ENTRE OTROS; R8 ES H, HALOGENO, METILO, ENTRE OTROS; R9 ES H, F, CN, ENTRE OTROS; R10 ES H, CF3, CN, METILO, ENTRE OTROS. SON COMPUESTOS PRERERIDOS: 3-[(S)-(4-CLOROFENIL)(3-{(1S)-2-FLUORO-1-[3-FLUORO-5-(5-OXO-4,5-DIHIDRO-1,3,4-OXADIAZOL-2-IL)FENIL]-2-METILPROPIL}AZETIDIN-1-IL)METIL]BENZONITRILO, 3-[(S)-(4-CLOROFENIL)(3-{(1S)-2-FLUORO-1-[3-FLUORO-5-(1,3,4-OXADIAZOL-2-IL)FENIL]-2-METILPROPIL}AZETIDIN-1-IL)METIL]BENZONITRILO, 3-[(S)-(3-{(1S)-1-[3-(5-AMINO-1,3,4-OXADIAZOL-2-IL)-5-FLUOROFENIL]-2-FLUORO-2-METILPROPIL}AZETIDIN-1-IL)(4-CLOROFENIL)METIL]BENZONITRILO, ENTRE OTROS. SE REFIERE TAMBIEN A UNA COMPOSICION FARMACEUTICA. DICHOS COMPUESTOS SON ANTAGONISTAS DEL RECEPTOR CANABINOIDE 1 (CB1) SIENDO UTILES PARA EL TRATAMIENTO DE PSICOSIS, ENFERMEDAD DE ALZHEIMER, MIGRANA, NEUROPATIA, ESCLEROSIS MULTIPLEREFERS TO COMPOUNDS DERIVED FROM 3-ALKYLAZETHYL DINE OF FORMULA (I) WHERE X IS HYDROXY, NH2, METHYL OR METHOXY; R2 AND R3 ARE EACH H, METHYL, TRIFLUOROMETHYL, AMONG OTHERS; R8 IS H, HALOGEN, METHYL, AMONG OTHERS; R9 IS H, F, CN, AMONG OTHERS; R10 IS H, CF3, CN, METHYL, AMONG OTHERS. THE PRERED COMPOUNDS ARE: 3 - [(S) - (4-CHLOROPHENYL) (3 - {(1S) -2-FLUORO-1- [3-FLUORO-5- (5-OXO-4,5-DIHYDRO-1, 3,4-OXADIAZOL-2-IL) PHENYL] -2-METHYLPROPYL} AZETIDIN-1-IL) METHYL] BENZONITRILE, 3 - [(S) - (4-CHLOROPHENYL) (3 - {(1S) -2-FLUORINE -1- [3-FLUORO-5- (1,3,4-OXADIAZOL-2-IL) PHENYL] -2-METHYLPROPYL} AZETIDIN-1-IL) METHYL] BENZONITRILE, 3 - [(S) - (3- {(1S) -1- [3- (5-AMINO-1,3,4-OXADIAZOL-2-IL) -5-FLUOROPHENYL] -2-FLUORO-2-METHYLPROPYL} AZETIDIN-1-IL) (4- CHLOROPHENYL) METHYL] BENZONITRILE, AMONG OTHERS. IT ALSO REFERS TO A PHARMACEUTICAL COMPOSITION. SUCH COMPOUNDS ARE CANABINOID RECEPTOR 1 (CB1) ANTAGONISTS, BEING USEFUL FOR THE TREATMENT OF PSYCHOSIS, ALZHEIMER'S DISEASE, MIGRANA, NEUROPATHY, MULTIPLE SCLEROSIS

PE2006001495A 2005-11-28 2006-11-23 3-ALKYLAZETHYL DINE DERIVATIVES SUBSTITUTED WITH HETEROCICLES AS ANTAGONISTS OF CANABINOID RECEPTOR 1 (CB1) PE20070647A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US74018305P 2005-11-28 2005-11-28

Publications (1)

Publication Number Publication Date
PE20070647A1 true PE20070647A1 (en) 2007-08-11

Family

ID=37779312

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2006001495A PE20070647A1 (en) 2005-11-28 2006-11-23 3-ALKYLAZETHYL DINE DERIVATIVES SUBSTITUTED WITH HETEROCICLES AS ANTAGONISTS OF CANABINOID RECEPTOR 1 (CB1)

Country Status (15)

Country Link
EP (1) EP1954692A1 (en)
KR (1) KR20080073721A (en)
AR (1) AR058199A1 (en)
BR (1) BRPI0619018A2 (en)
CR (1) CR10014A (en)
DO (1) DOP2006000261A (en)
EC (1) ECSP088477A (en)
IL (1) IL191586A0 (en)
MA (1) MA30086B1 (en)
NO (1) NO20082919L (en)
PE (1) PE20070647A1 (en)
RU (1) RU2008126248A (en)
SV (1) SV2009002917A (en)
TW (1) TW200804317A (en)
WO (1) WO2007062193A1 (en)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7906652B2 (en) 2005-11-28 2011-03-15 Merck Sharp & Dohme Corp. Heterocycle-substituted 3-alkyl azetidine derivatives
EP2025674A1 (en) 2007-08-15 2009-02-18 sanofi-aventis Substituted tetra hydro naphthalines, method for their manufacture and their use as drugs
AU2008317482A1 (en) * 2007-10-24 2009-04-30 Merck Sharp & Dohme Corp. Synthesis and crystalline forms of CB-1 antagonist/inverse agonist
WO2012031220A2 (en) 2010-09-03 2012-03-08 University Of Florida Research Foundation, Inc. Nicotine compounds and analogs thereof, synthetic methods of making compounds, and methods of use
WO2012120053A1 (en) 2011-03-08 2012-09-13 Sanofi Branched oxathiazine derivatives, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof
WO2012120056A1 (en) 2011-03-08 2012-09-13 Sanofi Tetrasubstituted oxathiazine derivatives, method for producing them, their use as medicine and drug containing said derivatives and the use thereof
WO2012120052A1 (en) 2011-03-08 2012-09-13 Sanofi Oxathiazine derivatives substituted with carbocycles or heterocycles, method for producing same, drugs containing said compounds, and use thereof
US8710050B2 (en) 2011-03-08 2014-04-29 Sanofi Di and tri- substituted oxathiazine derivatives, method for the production, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof
US8828994B2 (en) 2011-03-08 2014-09-09 Sanofi Di- and tri-substituted oxathiazine derivatives, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2805818B1 (en) * 2000-03-03 2002-04-26 Aventis Pharma Sa AZETIDINE DERIVATIVES, THEIR PREPARATION AND THE PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
FR2805810B1 (en) * 2000-03-03 2002-04-26 Aventis Pharma Sa PHARMACEUTICAL COMPOSITIONS CONTAINING 3- AMINO-AZETIDINE DERIVATIVES, THE NEW DERIVATIVES AND THEIR PREPARATION
FR2805817B1 (en) * 2000-03-03 2002-04-26 Aventis Pharma Sa PHARMACEUTICAL COMPOSITIONS CONTAINING AZETIDINE DERIVATIVES, NOVEL AZETIDINE DERIVATIVES AND THEIR PREPARATION
CN1802351A (en) * 2003-06-11 2006-07-12 麦克公司 Substituted 3-alkyl and 3-alkenyl azetidine derivatives
AU2006242219A1 (en) * 2005-05-02 2006-11-09 Merck & Co., Inc. Combination of dipeptidyl peptidase-IV inhibitor and a cannabinoid CB1 receptor antagonist for the treatment of diabetes and obesity

Also Published As

Publication number Publication date
MA30086B1 (en) 2008-12-01
NO20082919L (en) 2008-08-27
RU2008126248A (en) 2010-01-10
IL191586A0 (en) 2008-12-29
AR058199A1 (en) 2008-01-23
TW200804317A (en) 2008-01-16
CR10014A (en) 2008-07-29
KR20080073721A (en) 2008-08-11
BRPI0619018A2 (en) 2016-11-29
EP1954692A1 (en) 2008-08-13
ECSP088477A (en) 2008-06-30
SV2009002917A (en) 2009-02-19
DOP2006000261A (en) 2007-07-15
WO2007062193A1 (en) 2007-05-31

Similar Documents

Publication Publication Date Title
PE20110875A1 (en) DERIVATIVES OF ISOINDOL AS BACE INHIBITORS
PE20090617A1 (en) AMINO-5 - [- 4- (DIFLUOROMETOXI) PHENYL] -5-PHENYLIMIDAZOLONE COMPOUNDS FOR THE INHIBITION OF -SECRETASE
PE20001483A1 (en) OXAMIC ACIDS AND DERIVATIVES AS LIGANDS OF THYROID RECEPTORS
PE20091653A1 (en) SUBSTITUTE DERIVATIVES OF PIRAZOLE AND THEIR USE
PE20081229A1 (en) DIAZEPAM OREXIN RECEPTOR ANTAGONISTS REPLACED
PE20081665A1 (en) RAPID DISSOCIATION DOPAMINE 2 RECEPTOR ANTAGONISTS
PE20090297A1 (en) HETEROARYL-SUBSTITUTED PIRAZOLE DERIVATIVES USEFUL TO TREAT HYPERPROLIFERATIVE DISORDERS AND DISEASES ASSOCIATED WITH ANGIOGENESIS
PE20091431A1 (en) COMPOUNDS DERIVED FROM AZETIDINES, THEIR PREPARATION AND THEIR APPLICATION IN THERAPEUTICS
PE20091173A1 (en) HETEROARYL DERIVATIVES AS OREXIN RECEPTOR ANTAGONISTS
PE20070189A1 (en) AMINO-5-HETEROARYL COMPOUND (5 MEMBERS) IMIDAZOLONE AND ITS USE FOR ß-SECRETASE MODULATION
PE20061093A1 (en) PIPERAZINES SUBSTITUTED WITH HETEROCYCLES WITH ANTAGONIST ACTIVITY OF CXCR3
PE20080895A1 (en) DIHYDROPIRAZOLONES SUBSTITUTED AS INHIBITORS OF HIF-PROPIL-4-HYDROXYLASES
PE20070004A1 (en) IMIDAZOQUINOLINES AS LIPID KINASE INHIBITORS
PE20081472A1 (en) PIRAZOLINE COMPOUNDS
PE20091408A1 (en) COMPOUNDS AND COMPOSITIONS AS KINASE INHIBITORS
PE20070720A1 (en) DERIVATIVES OF PHENYL AS ANTAGONISTS OF HISTAMINE RECEPTOR 3
PE20120626A1 (en) PHARMACEUTICAL COMPOSITIONS INCLUDED BY NILOTINIB
PE20080056A1 (en) CHROMENCARBOXAMIDE DERIVATIVES AS ANTAGONISTS OF THE S1P1 RECEPTOR
PE20110237A1 (en) CYCLOHEXYLAMIDE DERIVATIVES AS ANTAGONISTS OF THE CORTICOTROPIN RELEASE FACTOR RECEPTOR (CRF-1)
NZ594641A (en) Pyrazole derivatives used as ccr4 receptor antagonists
PE20090890A1 (en) COMPOUNDS DERIVED FROM 1- (2,3-DIHIDROBENZO [1,4] DIOXIN-2-ILMETIL) AZACICLOS AS ANTAGONISTS OF SUPTIPO ADRENORECEPTOR ALFA2C
PE20120593A1 (en) FUSED DERIVATIVES OF PIRIMIDIN-4-ONA AS ANTAGONISTS OF THE ANGIOTENSIN II RECEPTOR AND AS AGONISTS OF THE PPAR GAMMA RECEPTOR
PE20061038A1 (en) DERIVATIVES OF 1,5-DIPHENYL-1H-PIRAZOL-3-IL) OXADIAZOLE AS CB1 ANTAGONIST AGENTS AND THEIR PREPARATION
PE20070647A1 (en) 3-ALKYLAZETHYL DINE DERIVATIVES SUBSTITUTED WITH HETEROCICLES AS ANTAGONISTS OF CANABINOID RECEPTOR 1 (CB1)
PE20090592A1 (en) NEW DERIVATIVES OF PIPERAZINE-AMIDE

Legal Events

Date Code Title Description
FD Application declared void or lapsed